CINCINNATI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System, today announced ...

Collaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies Under the terms of the agreement, ...

The MarketWatch News Department was not involved in the creation of this content. Enable Injections Announces Agreement with Sobi(R) to Develop and Distribute Aspaveli(R) in Combination with enFuse(R) ...

CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, today ...

CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® on-body drug delivery system, announced ...

CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System (OBDS), announced ...

CINCINNATI, Feb. 7, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse ® platform of wearable drug delivery systems, today ...

Under the terms of the agreement, Incyte will obtain a worldwide, exclusive license to use the enFuse technology with its mutCALR-targeted therapy (INCA033989) in essential thrombocythemia (ET) and ...

CINCINNATI, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, and ...